Massachusetts Financial Services CO Clovis Oncology, Inc. Transaction History

Massachusetts Financial Services CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.63 - $2.96 $79,914 - $375,473	-126,849 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$1.43 - $3.14 $1,861 - $4,088	1,302 Added 1.04%	126,849 $256,000
Q4 2021 Feb 10, 2022	SELL	$2.7 - $4.76 $6,860 - $12,095	-2,541 Reduced 1.98%	125,547 $340,000
Q3 2021 Nov 10, 2021	SELL	$4.06 - $5.8 $6,824 - $9,749	-1,681 Reduced 1.3%	128,088 $571,000
Q2 2021 Aug 13, 2021	BUY	$5.02 - $7.05 $5,587 - $7,846	1,113 Added 0.87%	129,769 $753,000
Q1 2021 May 13, 2021	SELL	$4.81 - $10.34 $73,338 - $157,653	-15,247 Reduced 10.6%	128,656 $903,000
Q4 2020 Feb 12, 2021	SELL	$4.13 - $6.41 $5,963 - $9,256	-1,444 Reduced 0.99%	143,903 $691,000
Q3 2020 Nov 12, 2020	BUY	$4.82 - $7.72 $700,572 - $1.12 Million	145,347 New	145,347 $847,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.